2023 could see approval of several new MOAs, as well as cell therapy for solid tumors and multiple bispecific T cell engagers
A few abstracts we'll be watching...
« Back to Pulse List
Oncology Pulse is our e-newsletter that looks at recent treads and promising directions in cancer treatments. Add your name to our maillist to receive future issues.
Bluestar BioAdvisors, LLC
521 Fifth Avenue, 25th Floor
New York, NY USA 10175
©2018–2023 Bluestar BioAdvisors, LLC. All rights reserved.